Immunex Message Board - Msg: 14281435

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Yang who started this subject	8/27/2000 4:10:07 AM
From: manfredhasler	of 656

Immunex Corporation (Nasdaq: IMNX) ($44.63) reiterated BUY on August 18, 2000 Buy Michael King Jr., Biopharmaceuticals "Physicians continue to grow in their reception of Enbrel for rheumatoid arthritis," said King. "We remain bullish in our predictions for Enbrel revenue growth both in the near and longer term. While production capacity remains an issue in the short-run, we remain confident that Immunex will meet our Enbrel sales estimates for 2001. Immunex is trading significantly lower than its 52-week high. We view this weakness as a buying opportunity for one our favorite big-cap biotech stocks and reiterate our Buy rating."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next